Guggenheim Upgrades Editas Medicine to Buy on EDIT-401 Cholesterol Therapy

Guggenheim raised Editas Medicine to Buy with a $5 target, citing EDIT-401’s potential in high-LDL ASCVD patients as its first human trial nears.